PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
48.96%
Some net income increase while CRVO is negative at -174.44%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.88%
Less SBC growth vs. CRVO's 100.00%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-128.88%
Both reduce yoy usage, with CRVO at -100.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-244.33%
Both negative yoy AP, with CRVO at -102.82%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
1043.06%
Growth well above CRVO's 107.38%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-114.48%
Negative yoy while CRVO is 160.55%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-59.54%
Negative yoy CFO while CRVO is 38.88%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.03%
Debt repayment growth of 2.03% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.